Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced it has completed enrollment in its Phase 2 EXPLORE-OSA trial evaluating lorundrostat in patients with moderate-to-severe obstructive sleep apnea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback